Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.8352W HIGH $41.14
Volume
1.62 M
Value Traded
48.58 M
Short % Float
11.78%
Days to Cover
10.5
+0.26%Week
+9.55%1 Month
+41.34%3 Month
+135.54%6 Month
-35.33%5 Year
-35.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.38 B
EPS (TTM)
-1.27
P/E Ratio
-
Ent. Value
2.61 B
Total Shares
111.42 M
Float Shares
108.88 M
Insiders
15.31%
Institutions
86.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AMLX Catalyst Timeline
Dated clinical, regulatory and corporate events for Amylyx Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amylyx Pharmaceuticals, Inc.
238Total events
17Upcoming
69Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutAvexitideClinical Data
Positive topline results from Phase 3 LUCIDITY trial of Avexitide in post-bariatric hypoglycemia
Post-Bariatric Hypoglycemiasource ↗
◆Topline ReadoutAvexitideClinical Data
Topline data readout for Phase 3 LUCIDITY of avexitide in PBH
post-bariatric hypoglycemiasource ↗
▼Equity OfferingCorporate
Pricing of upsized $500 million underwritten public offering of common stock
▲Topline ReadoutAvexitideClinical Data
Positive topline results from Phase 3 LUCIDITY trial
post-bariatric hypoglycemiasource ↗
▼Equity OfferingCorporate
Amylyx commences $350.0 million underwritten public offering of common stock
▲Primary Endpoint MetAvexitideClinical Data
LUCIDITY met FDA-agreed-upon primary endpoint
post-bariatric hypoglycemiasource ↗
●Last Patient Last VisitAvexitideTrial
Last participant completed final study visit in the 16-week double-blind period of Phase 3 LUCIDITY
post-bariatric hypoglycemiasource ↗
▲Topline ReadoutAvexitideClinical Data
Positive topline results from Phase 3 LUCIDITY trial of avexitide in PBH announced
post-bariatric hypoglycemia (PBH)source ↗
▼Equity OfferingCorporate
Closed underwritten public offering with net proceeds of approximately $544.6 million
◆Topline ReadoutAvexitideClinical Data
Topline data from Avexitide Phase 3 LUCIDITY trial in PBH
post-bariatric hypoglycemia (PBH)source ↗
▲Partnership / LicenseCorporate
Second research collaboration with Gubra A/S for rare endocrine disease
rare endocrine diseasesource ↗
▲Primary Endpoint MetAvexitideClinical Data
LUCIDITY met primary endpoint: 55% reduction in Level 2/3 hypoglycemic events (p=0.000003)
post-bariatric hypoglycemiasource ↗
▲Topline ReadoutAvexitideClinical Data
Positive topline results from Phase 3 LUCIDITY trial of avexitide in PBH
post-bariatric hypoglycemiasource ↗
●Oral PresentationAMX0114Presentation
Presented Phase 1 LUMINA data from initial two dose cohorts at Annual NEALS Meeting
amyotrophic lateral sclerosissource ↗
▲Enrollment CompleteAMX0114Trial
Completed enrollment of Cohort 3 (n=12) in Phase 1 LUMINA trial of AMX0114
amyotrophic lateral sclerosissource ↗
●Enrollment UpdateAMX0114Trial
Began enrollment of Cohort 4 in Phase 1 LUMINA trial of AMX0114
amyotrophic lateral sclerosissource ↗
◆Oral PresentationAMX0114Presentation
Data presentation from Phase 1 LUMINA trial of AMX0114 in ALS at ENCALS 2026
ALSsource ↗
◆Poster PresentationAvexitidePresentation
Poster presentation: Participant-Informed Design Considerations in Phase 3 LUCIDITY Trial of Avexitide for Post-Bariatric Hypoglycemia
post-bariatric hypoglycemiasource ↗
◆Poster PresentationAvexitidePresentation
Poster presentation: Characterizing the Burden of Post-Bariatric Hypoglycemia in the United States
post-bariatric hypoglycemiasource ↗
◆Oral PresentationAMX0114Presentation
Presentation of early biomarker data from Cohort 1 of Phase 1 LUMINA trial of AMX0114 in ALS at ENCALS 2026
amyotrophic lateral sclerosissource ↗
●Poster PresentationPresentation
Two posters on PBH burden and LUCIDITY trial design at ENDO 2026
post-bariatric hypoglycemiasource ↗
▲Additional DataAMX0114Clinical Data
Phase 1 LUMINA data for AMX0114 presented at ENCALS 2026
amyotrophic lateral sclerosissource ↗
▲Long Term DataAMX0035ApprovedClinical Data
HELIOS Week 96 longer-term data for AMX0035 presented
Wolfram syndromesource ↗
▲Development Candidate NominationAMX0318Preclinical
AMX0318 selected as development candidate for PBH and other rare diseases
post-bariatric hypoglycemia and other rare diseasessource ↗
▲Other Regulator MilestoneEx-US Regulatory
U.S. Expanded Access Program for adults with post-bariatric hypoglycemia
post-bariatric hypoglycemiasource ↗
▲Expanded AccessAvexitideFDA Decision
Initiation of U.S. Expanded Access Program for avexitide in PBH
post-bariatric hypoglycemiasource ↗
▲PublicationAMX0035ApprovedPresentation
HELIOS Week 24 and Week 48 results published in The Journal of Clinical Investigation
Wolfram syndromesource ↗
▲Development Candidate NominationAMX0318Preclinical
AMX0318 selected as development candidate
post-bariatric hypoglycemia (PBH) and other rare diseasessource ↗
▲Enrollment CompleteAvexitideTrial
Recruitment of LUCIDITY trial complete
post-bariatric hypoglycemia (PBH)source ↗
▲Enrollment CompleteAMX0114Trial
Completed enrollment in Cohort 2 of LUMINA Phase 1 trial of AMX0114 in ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
●Last Patient Last VisitAvexitideTrial
Last eligible participants to be randomized and dosed
post-bariatric hypoglycemia (PBH)source ↗
▲Enrollment CompleteAvexitideTrial
Complete recruitment of Avexitide Phase 3 trial in PBH
post-bariatric hypoglycemia (PBH)source ↗
●Oral PresentationAMX0114Presentation
Biomarker signature of calpain-2 activity in ALS and preclinical model data presented
ALSsource ↗
▲Oral PresentationAMX0114Presentation
Safety and tolerability data from cohort 1 presented at MNDA symposium
ALSsource ↗
▲Enrollment UpdateAMX0114Trial
Enrollment of second cohort to begin in Canada in December 2025 and US in January 2026
ALSsource ↗
▲Oral PresentationAMX0114Presentation
Early safety and tolerability data from Cohort 1 of LUMINA presented at MNDA
amyotrophic lateral sclerosis (ALS)source ↗
◆Development Candidate NominationPreclinical
Decision on potential development candidate for novel long-acting GLP-1 receptor antagonist from Gubra collaboration
▲Enrollment CompleteAMX0114Trial
Fully enrolled cohort 1 of Phase 1 LUMINA trial of AMX0114 in ALS
ALSsource ↗
Past FDA Catalysts and PDUFA Decisions
How AMLX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-18 | avexitide | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 19%
Small Cap(rank 132 of 689)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMX0035 Small MoleculesNCT05676034 | Wolfram Syndrome | Phase 2 | ACTIVE NOT_RECRUITING | 12 | May 31, 2028 | ||||||
| AMX0114 Small MoleculesNCT06665165 | ALS | Phase 1 | RECRUITING | 48 | Oct 1, 2027 | ||||||
| Avexitide PeptidesNCT06747468 | Post Bariatric Hypoglycemia | Phase 3 | ACTIVE NOT_RECRUITING | 75 | Feb 1, 2027 | ||||||
| AMX0035 Small MoleculesCompletedNCT06122662 | Progressive Supranuclear Palsy | Phase 2/3 | COMPLETED | 139 | Oct 21, 2025 | ||||||
| AMX0035 Small MoleculesCompletedNCT03533257 | Alzheimer Disease | Phase 2 | COMPLETED | 95 | Nov 6, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every AMLX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| avexitide BreakthroughOrphanRare Pediatric | post-bariatric hypoglycemia | Phase 3 | 2026-11-04 | highly statistically significant reductions in hypoglycemic eventsRead More | Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH ExpertsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FRATES JAMES MOfficer (Chief Financial Officer) | Option | 20,000 253,625 held | $6.88 | 11/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AMLX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 2.2 % (-4.3 %) | 149.69 M | 8.33 M | 0.6% ( 50.00 K) |
Ownership Trends
AMLX Short Interest
Shares sold short, counted twice a month.
11.78%
Short % of Float
of tradable shares sold short
12.8M
Shares Sold Short
-3.2% vs prior count
10.5 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AMLX ranks across every disease it competes in
Competitive Position is a premium feature
See how AMLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAMLX News
AMLX▼ -6.1%on this news
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
Amylyx Pharmaceuticals reported positive topline results from the Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia. The trial met its primary endpoint with a 55% reduction in hypoglycemic events. The company plans to submit a New Drug Application by the end of 2026 and has strengthened its financial position with a recent public offering.
Read more →AMLXAmylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
Amylyx Pharmaceuticals will host an investor event at ObesityWeek 2026 on November 15, featuring insights on post-bariatric hypoglycemia (PBH) from leading experts. The event will include results from the Phase 3 LUCIDITY trial of avexitide, which demonstrated significant efficacy in reducing hypoglycemic events in patients post-RYGB surgery. The webcast will be available for 90 days post-event.
Read more →AMLXAmylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Amylyx Pharmaceuticals will participate in two investor conferences in November 2026. The conferences include the Guggenheim 3rd Annual Healthcare Innovation Conference and the Stifel 2026 Healthcare Conference. Both events will feature fireside chats and will be accessible via live webcasts for 90 days post-event.
Read more →AMLXAmylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Amylyx Pharmaceuticals plans to report its third quarter 2026 financial results on November 5, 2026. A conference call will be held at 8:00 a.m. ET for management to discuss the results and company updates. The company emphasizes its commitment to addressing diseases with high unmet needs through investigational therapies.
Read more →AMLXAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Amylyx Pharmaceuticals will present topline data from its Phase 3 LUCIDITY clinical trial of Avexitide, aimed at treating post-bariatric hypoglycemia. This presentation is scheduled for the ObesityWeek 2026 Annual Meeting, highlighting the company's advancements in addressing this condition. The event is expected to attract significant attention in the obesity treatment community.
Read more →AMLX▼ -7.3%on this news
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Amylyx Pharmaceuticals has announced its participation in the Stifel 2026 Virtual Cardiometabolic Forum. This event will provide the company with a platform to engage with investors and showcase its developments in the cardiometabolic space. The presentation is expected to enhance visibility and foster potential collaborations.
Read more →AMLXAmylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Amylyx Pharmaceuticals is set to present at the 24th Annual Morgan Stanley Global Healthcare Conference. This event provides a platform for the company to showcase its developments and engage with investors. Participation in such a prominent conference underscores Amylyx's strategic focus on growth and innovation in the biopharma sector.
Read more →AMLXAmylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Amylyx Pharmaceuticals has successfully priced an upsized public offering of 14,090,000 shares at $35.50 each, raising $500 million. The company has also provided underwriters with a 30-day option to purchase an additional 2,113,500 shares. This move reflects strong market interest and aims to support the company's growth initiatives.
Read more →AMLX▲ +9.9%on this newsshared move
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
Amylyx Pharmaceuticals has announced a public offering of $350 million in common stock. The company also plans to give underwriters a 30-day option to buy an additional $52.5 million in shares. This move aims to enhance its financial resources for future initiatives.
Read more →AMLX▲ +63.8%on this news· ran to +80% by day 3shared move
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY trial, which evaluated avexitide for treating post-bariatric hypoglycemia. The study included 78 participants and was designed as a multicenter, randomized, double-blind, placebo-controlled trial. These results suggest that avexitide may be an effective treatment option for patients experiencing hypoglycemia after Roux-en-Y gastric bypass.
Read more →AMLX▲ +63.8%on this news· ran to +80% by day 3shared move
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
Amylyx Pharmaceuticals is set to announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide, targeting Post-Bariatric Hypoglycemia, on August 18, 2026. The announcement will be followed by a conference call hosted by the senior management team. This trial represents a crucial step in the company's clinical development efforts.
Read more →AMLX▲ +10.7%on this news
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
Amylyx Pharmaceuticals has reported its financial results for the second quarter of 2026. The announcement was made from their headquarters in Cambridge, Massachusetts. Details regarding revenue, expenses, and other financial metrics were not provided in the brief report.
Read more →AMLXAmylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Amylyx Pharmaceuticals has announced that it will report its financial results for the second quarter of 2026 on August 6, 2026. This announcement is part of their regular financial reporting schedule. The company is based in Cambridge, Massachusetts, and is focused on developing therapies for neurological diseases.
Read more →AMLXAmylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Amylyx Pharmaceuticals is set to present data from the first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 in ALS at the upcoming ENCALS 2026 conference. This trial aims to evaluate the safety and efficacy of AMX0114 for patients with Amyotrophic Lateral Sclerosis (ALS). The presentation will provide insights into the trial's findings and implications for future research.
Read more →AMLXAmylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
Amylyx Pharmaceuticals announced two poster presentations at ENDO 2026, focusing on post-bariatric hypoglycemia (PBH) and the LUCIDITY trial of avexitide. The first presentation discusses the burden of PBH on healthcare, while the second outlines participant-centric trial design for avexitide, a GLP-1 receptor antagonist. Avexitide has received Breakthrough Therapy Designation from the FDA.
Read more →AMLX▼ -5.4%on this news
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
Amylyx Pharmaceuticals reported its financial results for Q1 2026, highlighting that cash resources should support operations through potential avexitide commercialization and into 2028. The company has completed enrollment in its Phase 3 LUCIDITY trial for avexitide, with topline data expected in Q3 2026. The treatment, aimed at post-bariatric hypoglycemia, has received FDA Breakthrough Therapy Designation, indicating regulatory support. However, the company experienced an increase in both net loss and R&D expenses during the quarter.
Read more →AMLXAmylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals has announced the initiation of a U.S. Expanded Access Program for adults suffering from post-bariatric hypoglycemia. This program aims to provide access to their treatment for patients who may not qualify for clinical trials. The announcement highlights the company's commitment to addressing this condition.
Read more →AMLXMARCH 2026 We have an audacious mission to develop novel therapies for diseases with high unmet needs, with a focus on serious and fatal endocrine conditions and neurodegenerative diseases. Maggie, a mom and advocate liv
Amylyx Pharmaceuticals is advancing its novel therapies targeting diseases with high unmet needs, particularly focusing on post-bariatric hypoglycemia and neurodegenerative conditions. Upcoming clinical trials, including the Phase 3 LUCIDITY trial for avexitide, are expected to provide significant data by Q3 2026. The company is collaborating with various experts to ensure efficient development and regulatory strategies. While there is enthusiasm for their pipeline, there are inherent uncertainties and financial risks involved in the clinical processes and overall operational sustainability.
Read more →AMLX▼ -7.8%on this news
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Amylyx Pharmaceuticals reported its financial results for Q4 and full year 2025, highlighting progress in its avexitide program for post-bariatric hypoglycemia (PBH). The company has completed recruitment for its Phase 3 LUCIDITY trial and anticipates topline data in Q3 2026. Additionally, early data from the Phase 1 LUMINA trial of AMX0114 for ALS showed promising safety results. Despite a net loss of $144.7 million for the year, Amylyx maintains a strong cash position extending into 2028.
Read more →AMLX▲ +6.2%on this newsshared move
Amylyx Pharmaceuticals to Participate in Upcoming March 2026 Investor Conferences
Amylyx Pharmaceuticals has announced its participation in upcoming investor conferences in March 2026. The company will provide live webcasts of the presentations, which will be available for replay for 90 days. Amylyx is dedicated to developing therapies for diseases with significant unmet needs, showcasing its commitment to innovation and community service.
Read more →About Amylyx Pharmaceuticals, Inc.
Headquarters55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142
Founded2013
BIOPHARMAWATCH ELITE
Trade the next AMLX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime